Fernanda Bordignon Nunes

Dr. Fernanda Bordignon Nunes

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BCBruna Pasqualotto Costa
Bruna Pasqualotto Costa
FNFernanda Bordignon Nunes
Fernanda Bordignon Nunes
FNFrancini Corrêa Noal
Francini Corrêa Noal
GBGisele Branchini
Gisele Branchini
Uterine or endometrial cancer (EC) is the sixth most common neoplasia among women worldwide. Cancer can originate from a myriad of causes, and increasing evidence suggests that ion channels (IC) play an important role in the process of carcinogenesis, taking part in many pathways such as self-sufficiency in growth signals, proliferation, evasion of programmed cell death (apoptosis), angiogenesis, cell differentiation, migration, adhesion, and metastasis. Hormones and growth factors are well-known to be involved in the development and/or progression of many cancers and can also regulate some ion channels and pumps. Since the endometrium is responsive and regulated by these factors, the ICs could make an important contribution to the development and progression of endometrial cancer. In this review, we explore what is beyond (ion) flow regulation by investigating the role of the main families of ICs in EC, including as possible targets for EC treatment.

20 June 2023 in Journal of Forensic and Legal Medicine
Verified
Journal Article
Closed access
ENEduardo Novakoski
Eduardo Novakoski
GBGisele Branchini
Gisele Branchini
TOTiago Franco de Oliveira
Tiago Franco de Oliveira
JKJulia Flôres Kuhn
Julia Flôres Kuhn
SMSarah Bueno Motter
Sarah Bueno Motter
FNFernanda Bordignon Nunes
Fernanda Bordignon Nunes

15 November 2022 in Cureus
Verified
Journal Article
Open access
LDLetícia Dupont
Letícia Dupont
RDRodrigo P. Duquia
Rodrigo P. Duquia
GPGustavo W. Pizutti
Gustavo W. Pizutti
FNFernanda Bordignon Nunes
Fernanda Bordignon Nunes
GBGisele Branchini
Gisele Branchini
RBRenan R. Bonamigo
Renan R. Bonamigo
The aim of this study was to ascertain whether pattern of cutaneous lesions, age, sex, ethnicity, long-term medication use, arterial oxygen saturation at the first examination, setting of care, and number of medications used to treat SARS-CoV-2 infection are associated with mortality in patients with a confirmed diagnosis of coronavirus disease 2019 (COVID-19) and cutaneous manifestations. In addition, to evaluate the occurrence of cutaneous manifestations in patients with a confirmed diagnosis of COVID-19 through a review of medical records and in-person evaluation by a dermatologist. This investigation consisted of two components - (A) a cross-sectional study with a retrospective review of the medical records of all patients with a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 treated at Santa Casa de Misericórdia de Porto Alegre between March 2020 and November 2020, and (B) a prospective case series with in-person skin examination by an attending dermatologist of all patients admitted to COVID-19 wards between April 2021 and July 2021. The pattern of skin lesions and other variables were assessed. Information from 2968 individuals with COVID-19 was collected (2826 from the medical records and 142 from the in-person examination by a dermatologist). Of these, a total of 51 patients (1.71%) had COVID-19-related cutaneous lesions - 36 from the medical records group (1.27% of cutaneous manifestations) and 15 from the examinated group (10.56% of cutaneous manifestations). Of 51 patients, 15 (29.41%) died. There was no association between mortality and patterns of cutaneous manifestations. The variables male sex (p=0.021), intensive care unit (ICU) admission (p=0.001), and use of three or more antibiotics (p=0.041) were associated with higher mortality. The risk factors, proven by our study, for mortality in patients with COVID-19 and cutaneous manifestations were male sex, ICU stays, and use of three or more antibiotics. Using the review of medical records as a tool for evaluating cutaneous manifestations related to COVID-19, there are about 10 times fewer occurrences when compared to in-person evaluation by a dermatologist.